Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou've decided to stop taking Wegovy, or you're seriously considering it. That's a real and common situation — stopping a semaglutide injection means your appetite signals, gastric emptying rate and blood-sugar regulation all begin shifting back toward where they were before treatment started. There's no dangerous withdrawal, but the body does adjust, and understanding what that looks like helps you plan. Wegovy (semaglutide) is a prescription-only medicine; any decision to stop, pause or taper should be made with your prescribing clinician, not unilaterally, because the right exit strategy depends on where you are in your treatment and what you're aiming for next.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you took your last Wegovy pen two weeks ago. You've noticed food is on your mind more than it was. The portion that felt like plenty at lunch now barely touches the sides. That's not a failure of willpower, it's pharmacology reversing itself. Semaglutide suppresses appetite by activating GLP-1 receptors in the brain's hunger centres and slowing gastric emptying. When semaglutide clears, those pathways revert.
Because the drug's half-life is approximately one week, blood levels fall over roughly four to five weeks after the last injection. Appetite signals generally resurface gradually across that window rather than in one sharp rush, but the timeline varies by individual, dose and how long you'd been on treatment. The semaglutide overview covers the mechanism in more detail if you want the physiology behind it.
Gastrointestinal patterns may also shift. Some people experience a brief return of nausea or reflux as the gut motility changes again; others find constipation eases. These fluctuations are usually short-lived. If symptoms are severe or prolonged, speak to your GP or the prescriber who managed your treatment. The ondansetron and Wegovy page has relevant context on managing nausea during treatment, much of which applies to the transition period too.
This is the part most people are anxious about, and the data are honest rather than reassuring. Follow-up from the STEP 1 extension study showed that, one year after stopping semaglutide, participants had regained on average about two-thirds of the weight they'd lost during treatment. The STEP 1 trial, published in the New England Journal of Medicine, remains the key evidence base here.
That figure often prompts alarm, but context matters. It reflects what happens when treatment ends without a structured exit plan. People who stop abruptly, with no dietary adjustments and no increased activity, tend toward the higher end of regain. Those who use the period of appetite suppression to build habits (portion awareness, protein adequacy, regular movement) often hold more of their progress.
There is also a group for whom stopping is the intended outcome: people who reached their health goal, have consolidated new habits, and are ready to manage without medication. For them, planned discontinuation with clinical oversight is entirely appropriate. The getting off Wegovy guide covers tapering strategies and timing in more detail.
Weight management is a long-term clinical concern, not a course of antibiotics. That's not said to keep you on medication indefinitely, it's said so the plan for stopping is as considered as the plan for starting.
If you're stopping because treatment is complete, practical steps make a difference. First, don't stop on a bad week: stress, illness or a disrupted routine are poor backdrops for discontinuation. Second, talk to your prescriber before the last injection rather than after, the exit conversation should cover your target weight, your dietary habits now versus at the start, and any conditions (such as blood pressure or blood sugar) that were being managed partly via weight loss.
A gradual dose reduction is sometimes used clinically, though the evidence base for tapering versus abrupt cessation is limited; your prescriber's guidance takes precedence over any general rule. If you're stopping because of side effects rather than completion, that conversation is even more important: some side effects are manageable with dose adjustment or supportive medicines rather than full discontinuation.
For context on what private treatment looks like if you're considering restarting later, the weight-loss treatments overview lays out the options plainly. And if cost was a factor in your decision to stop, it's worth understanding what the private Wegovy prescription route actually includes, some people discover they were paying for less than they assumed elsewhere.
Whatever your reason for stopping, the commonly asked questions page addresses several practical follow-up scenarios. The detail on how to quit Wegovy is worth reading before your last injection, not after it. The getting semaglutide page is useful if you later decide to return to treatment and want to understand the process afresh. The NHS semaglutide medicines page also summarises what to expect when stopping and when to seek help.
If you'd like to discuss your options with a prescriber before making a final decision, you can check your eligibility for a consultation with the nume clinical team, no commitment required.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.